<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39606594</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1642-395X</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Postepy dermatologii i alergologii</Title><ISOAbbreviation>Postepy Dermatol Alergol</ISOAbbreviation></Journal><ArticleTitle>LED-emitted blue light improves quality of life and reduces fatigue after COVID-19 infection.</ArticleTitle><Pagination><StartPage>515</StartPage><EndPage>520</EndPage><MedlinePgn>515-520</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5114/ada.2024.144522</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Despite multiple clinical presentations of long COVID, the most common symptom encountered by the patients is fatigue which significantly impacts daily functioning and quality of life. There are, however, multiple unanswered questions regarding the treatment of fatigue among long COVID patients. Several studies highlighted that repetitive exposure to blue light may alleviate the fatigue in different groups of patients but the studies on the efficacy of blue light therapy in treatment of fatigue in long COVID patients are lacking.</AbstractText><AbstractText Label="AIM" NlmCategory="UNASSIGNED">To evaluate the effects of blue light therapy in treatment of fatigue among COVID-19 survivors.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">The study comprised of 43 adults who underwent COVID-19 infection with a subjective feeling of fatigue 4 weeks after the infection. All participants underwent 10 full-body blue light irradiation for 15 min a day for 5 consecutive days each week. All participants were assessed using the Fatigue Severity Scale (FSS), Short Form 36 Vitality Subscale (SF-36) and Dermatology Life Quality Index (DLQI). Serum samples were taken to measure the levels of tryptophan, kynurenine, kynurenic acid, quinolinic acid and serotonin before and after irradiation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Irradiation with blue light resulted in a significant decrease in FSS and DLQI as well as in an increase in SF-36 and serum levels of tryptophan, kynurenine and serotonin.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Our study shows that blue light therapy could be used as adjunctive treatment of fatigue and provide an opportunity for further scientific inquiries.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Termedia Sp. z o. o.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nolberczak</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Paediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesiak</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Paediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czajkowski</LastName><ForeName>Rafa&#x142;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Dermatology and Venerology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bednarski</LastName><ForeName>Igor Aleksander</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narbutt</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Paediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Postepy Dermatol Alergol</MedlineTA><NlmUniqueID>101168357</NlmUniqueID><ISSNLinking>1642-395X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FSS</Keyword><Keyword MajorTopicYN="N">SF-36 scale</Keyword><Keyword MajorTopicYN="N">blue light therapy</Keyword><Keyword MajorTopicYN="N">post-COVID fatigue</Keyword><Keyword MajorTopicYN="N">psychological consequences of COVID</Keyword></KeywordList><CoiStatement>The research was conducted with co-operation with Phlecs (Eindhoven, Netherlands).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>5</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39606594</ArticleId><ArticleId IdType="pmc">PMC11589642</ArticleId><ArticleId IdType="doi">10.5114/ada.2024.144522</ArticleId><ArticleId IdType="pii">55046</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coronavirus disease (COVID-19) , (n.d.). https://www.who.int/news-room/fact-sheets/detail/coronavirus-disease-(covid-19) (accessed February 13, 2024).</Citation></Reference><Reference><Citation>Akbarialiabad H, Taghrir MH, Abdollahi A, et al. . Long COVID, a comprehensive systematic scoping review. Infection 2021; 49: 1163-86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8317481</ArticleId><ArticleId IdType="pubmed">34319569</ArticleId></ArticleIdList></Reference><Reference><Citation>Giussani G, Westenberg E, Garcia-Azorin D, et al. . Prevalence and trajectories of post-COVID-19 neurological manifestations: a systematic-review and meta-analysis. Neuroepidemiology 2024; 58: 120-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">38272015</ArticleId></ArticleIdList></Reference><Reference><Citation>Schurr M, Junne F, Martus P, et al. . SARS-CoV-2 infection is associated with physical but not mental fatigue &#x2013; findings from a longitudinal controlled population-based study. J Psychosom Res 2024; 178: 111598.</Citation><ArticleIdList><ArticleId IdType="pubmed">38277895</ArticleId></ArticleIdList></Reference><Reference><Citation>Premraj L, Kannapadi NV, Briggs J, et al. . Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci 2022; 434: 120162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8798975</ArticleId><ArticleId IdType="pubmed">35121209</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinzon RT, Wijaya VO, Al Jody A, et al. . Persistent neurological manifestations in long COVID-19 syndrome: a systematic review and meta-analysis. J Infect Public Health 2022; 15: 856-69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9221935</ArticleId><ArticleId IdType="pubmed">35785594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, et al. . Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun 2022; 101: 93-135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, et al. . Long COIVID-mechanisms, risk factors, and management. BMJ 2021; 374: n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WJ, Hui CKM, Hull JH, et al. . Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med 2021; 9: 533-44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8041436</ArticleId><ArticleId IdType="pubmed">33857435</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavanagh E. Long Covid brain fog: a neuroinflammation phenomenon? Oxf Open Immunol 2022; 3: iqac007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9914477</ArticleId><ArticleId IdType="pubmed">36846556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ero&#x11f;lu &#x130;, Ero&#x11f;lu B&#xc7;, G&#xfc;ven GS. Altered tryptophan absorption and metabolism could underlie long-term symptoms in survivors of coronavirus disease 2019 (COVID-19). Nutrition 2021; 90: 111308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8087860</ArticleId><ArticleId IdType="pubmed">34111831</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim HK, Abed AK, Almulla AF, et al. . Anxiety due to Long COVID is partially driven by activation of the tryptophan catabolite (TRYCAT) pathway. Asian J Psychiatr 2023; 88: 103723.</Citation><ArticleIdList><ArticleId IdType="pubmed">37567082</ArticleId></ArticleIdList></Reference><Reference><Citation>Platten M, Nollen EAA, R&#xf6;hrig UF, et al. . Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov 2019; 18: 379-401.</Citation><ArticleIdList><ArticleId IdType="pubmed">30760888</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res 2009; 2: 1-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3195227</ArticleId><ArticleId IdType="pubmed">22084578</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita M. Potential role of neuroactive tryptophan metabolites in central fatigue: establishment of the fatigue circuit. Int J Tryptophan Res 2020; 13: 1178646920936279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7325545</ArticleId><ArticleId IdType="pubmed">32647476</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang HJ, Lin CW, Hsiao MY, et al. . Long COVID and rehabilitation. J Formos Med Assoc 2024; 123 Suppl 1: S61-S69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10101546</ArticleId><ArticleId IdType="pubmed">37061399</ArticleId></ArticleIdList></Reference><Reference><Citation>Chee YJ, Fan BE, Young BE, et al. . Clinical trials on the pharmacological treatment of long COVID: a systematic review. J Med Virol 2023; 95: e28289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878018</ArticleId><ArticleId IdType="pubmed">36349400</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21: 133-46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Srisurapanont K, Samakarn Y, Kamklong B, et al. . Blue-wavelength light therapy for post-traumatic brain injury sleepiness, sleep disturbance, depression, and fatigue: a systematic review and network meta-analysis. PLoS One 2021; 16: e0246172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7861530</ArticleId><ArticleId IdType="pubmed">33539446</ArticleId></ArticleIdList></Reference><Reference><Citation>Racz E, Prens EP. Phototherapy and photochemotherapy for psoriasis. Dermatol Clin 2015; 33: 79-89.</Citation><ArticleIdList><ArticleId IdType="pubmed">25412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim HW, Silpa-archa N, Amadi U, et al. . Phototherapy in dermatology: a call for action. J Am Acad Dermatol 2015; 72: 1078-80.</Citation><ArticleIdList><ArticleId IdType="pubmed">25981004</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstabl A, Hoff-Lesch S, Merk HF, von Felbert V. Prospective randomized study on the efficacy of blue light in the treatment of psoriasis vulgaris. Dermatology 2011; 223: 251-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22105015</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff S, Liebmann J, Born M, et al. . Prospective randomized long-term study on the efficacy and safety of UV-free blue light for treating mild psoriasis vulgaris. Dermatology 2015; 231: 24-34.</Citation><ArticleIdList><ArticleId IdType="pubmed">26044167</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebmann J, Born M, Kolb-Bachofen V. Blue-light irradiation regulates proliferation and differentiation in human skin cells. J Invest Dermatol 2010; 130: 259-69.</Citation><ArticleIdList><ArticleId IdType="pubmed">19675580</ArticleId></ArticleIdList></Reference><Reference><Citation>Awakowicz P, Bibinov N, Born M, et al. . Biological stimulation of the human skin applying health promoting light and plasma sources. Contrib. Plasma Phys 2009; 49: 641-7.</Citation></Reference><Reference><Citation>Fischer MR, Abel M, Lopez Kostka S, et al. . Blue light irradiation suppresses dendritic cells activation in vitro. Exp Dermatol 2013; 22: 558-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">23879817</ArticleId></ArticleIdList></Reference><Reference><Citation>Do A, Li VW, Huang S, et al. . Blue-light therapy for seasonal and non-seasonal depression: a systematic review and meta-analysis of randomized controlled trials. Can J Psychiatry 2022; 67: 745-54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9511000</ArticleId><ArticleId IdType="pubmed">35522196</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly LJ, Rajaratnam SMW, Murray JM, et al. . Home-based light therapy for fatigue following acquired brain injury: a pilot randomized controlled trial. BMC Neurol 2021; 21: 262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8256500</ArticleId><ArticleId IdType="pubmed">34225698</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu HS, Gao F, Yan L, Given C. Evaluating chronotypically tailored light therapy for breast cancer survivors: preliminary findings on fatigue and disrupted sleep. Chronobiol Int 2022; 39: 221-32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8792175</ArticleId><ArticleId IdType="pubmed">34732099</ArticleId></ArticleIdList></Reference><Reference><Citation>Paradiso B, Limback C, Su T, et al. . Editorial: an update on neurological disorders post COVID-19 infection. Front Neurol 2023; 14: 1229843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10374834</ArticleId><ArticleId IdType="pubmed">37521288</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-M&#xe1;rmol R, Giordano-Santini R, Kaulich E, et al. . SARS-CoV-2 infection and viral fusogens cause neuronal and glial fusion that compromises neuronal activity. Sci Adv 2023; 9: eadg2248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10246911</ArticleId><ArticleId IdType="pubmed">37285437</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn CH, Lam RW. Update on the biology of seasonal affective disorder. CNS Spectr 2005; 10: 635-46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16041295</ArticleId></ArticleIdList></Reference><Reference><Citation>Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science 2002; 295: 1070-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">11834835</ArticleId></ArticleIdList></Reference><Reference><Citation>Pail G, Huf W, Pjrek E, et al. . Bright-light therapy in the treatment of mood disorders. Neuropsychobiology 2011; 64: 152-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">21811085</ArticleId></ArticleIdList></Reference><Reference><Citation>Badawy AAB. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res 2017; 10: 1178646917691938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5398323</ArticleId><ArticleId IdType="pubmed">28469468</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim HK, Khairi Abed A, Rouf Moustafa S, et al. . Tryptophan catabolites, inflammation, and insulin resistance as determinants of chronic fatigue syndrome and affective symptoms in long COVID. Front Mol Neurosci 2023; 16: 1194769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10272345</ArticleId><ArticleId IdType="pubmed">37333619</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res 2012; 196: 243-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22364930</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012; 13: 465-77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681811</ArticleId><ArticleId IdType="pubmed">22678511</ArticleId></ArticleIdList></Reference><Reference><Citation>Col&#xed;n-Gonz&#xe1;lez AL, Maldonado PD, Santamar&#xed;a A. 3-Hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system. Neurotoxicology 2013; 34: 189-204.</Citation><ArticleIdList><ArticleId IdType="pubmed">23219925</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>